Medline IPO
Tradingprice, listing and company profile
IPO price$29.00Price range: $26.00 – $29.00
Deal size$6.3B216,034,482 shares
Valuation$37BIPO valuation
- IPO filing
- Roadshow
- Pricing
- First trade
- Quiet period
- Lockup
Performance since IPO
Confirmed share price history
No published trading history yet
IPO recap
Confirmed offering terms
Medline filed IPO documents on Dec 8, 2025. Confirmed offering terms are shown below.
FiledDec 8
PricingDec 16
First tradeDec 17
Lockup ends—
The short version
Medline has traded publicly since 2025-12-17. This profile covers the final price, share count, proceeds, business model, operating context and key risks.
Key takeaway 1
Medline priced 216.0 million shares at $29 and began Nasdaq trading on 17 December 2025.
Key takeaway 2
The offering was one of the largest recent U.S. IPOs by gross proceeds.
Key takeaway 3
The business combines medical manufacturing, distribution and procurement scale.
Company in detail
What happened at the IPO
Medline priced its initial public offering at $29.00 per share and began trading on 2025-12-17 on the Nasdaq under MDLN. The final price, base share count and gross size are the confirmed transaction terms; they are separate from later market performance.
The deal included 216,034,482 base shares and an over-allotment option for 32,405,172 additional shares. The upsized offering included new Class A shares and a full over-allotment option; the prospectus described sponsor ownership and structural transactions.
Company and products
Medline is Medical-supply manufacturer and distributor serving healthcare providers. Its core offering includes Surgical supplies, exam gloves, procedure kits, lab products and supply-chain services.
Medline operates at scale across hospitals, clinics and care settings where product availability and purchasing efficiency matter. The company’s route to scale therefore depends on both product demand and the operating discipline needed to serve that demand.
Capital, ownership and use of proceeds
The registration materials described the capital structure and the distinction between new shares and shares sold by existing holders. General corporate purposes, capital structure and transactions involving pre-IPO ownership interests.
The headline gross offering value is not the same as cash retained by the issuer. Underwriting discounts, offering expenses, selling-stockholder proceeds and any concurrent securities must be read separately in the final prospectus.
Financial and operating lens
Healthcare supply chain: Medical products and distribution at national scale. Medline’s operating model is built around procurement, manufacturing, logistics and provider relationships rather than a single end product.
The public-market analysis should connect this operating measure to revenue quality, cash conversion, customer or user retention and the cost of expanding the platform. IPO proceeds can extend the runway, but they do not remove execution risk.
Why this IPO matters
Medline brought a large, established healthcare-supply business to market and made private-equity ownership and debt structure visible to public investors.
The main questions after the first trade are whether the company can deliver on its stated growth plan, preserve service quality and turn the IPO story into durable public-company results.
- Hospitals, supply-chain execution, leverage and sponsor ownership are the core public-market questions.
Operating metrics
Healthcare supply chain
Medical products and distribution at national scaleMedline’s operating model is built around procurement, manufacturing, logistics and provider relationships rather than a single end product.
Dec 8, 2025Company profile
- Founded
- 1966
- Legal name
- Medline Inc.
- Listing
- Nasdaq · MDLN
- Headquarters
- Northfield, Illinois, United States
- Business
- Medical-supply manufacturer and distributor serving healthcare providers.
- Products
- Surgical supplies, exam gloves, procedure kits, lab products and supply-chain services.
- IPO structure
- The upsized offering included new Class A shares and a full over-allotment option; the prospectus described sponsor ownership and structural transactions.
- Use of proceeds
- General corporate purposes, capital structure and transactions involving pre-IPO ownership interests.
- First trade
- 2025-12-17
- Employees
- No published figure
Timeline
- Public registration filed
Medline moved from private preparation into a public registration process. Filing terms were preliminary and subject to later pricing.
- IPO priced
Medline announced a final price of $29.00 per share for the base offering.
- First trading day
The shares began trading on Nasdaq under MDLN.
- Closing confirmed
The issuer confirmed completion of the offering and the final capital-market structure.
Healthcare supply chain
Medical products and distribution at national scaleMedline’s operating model is built around procurement, manufacturing, logistics and provider relationships rather than a single end product.
Base shares offered
216,034,482Base deal size at the final price; the over-allotment option is shown separately.
Final IPO price
$29.00per shareFinal public offering price announced on 2025-12-16; this is the offer price, not a current market quote.
Employees
—No published figure
Net income
—No published figure
Operating cash flow
—No published figure
Financials
No complete financial history available
Revenue
Financial history unavailableComparable financial periods will appear here when available.
No comparable financial series
Available dated disclosures are included in the company overview. View disclosures →
Valuation & peers
Price-to-sales, revenue growth and gross margin
Comparable metrics unavailableComparable company figures for the same date are not available.
Revenue growth (%)
| Company | P/S | Growth | GM |
|---|---|---|---|
| Medline | — | — | — |
| No published peer comparison | |||
Context: Private financing valuations and modeled market values do not establish an IPO valuation. Revenue run-rate is not used here to calculate a price-to-sales ratio.
Private valuation and funding details
Final IPO price
$29.00 per shareFinal public offering price announced on 2025-12-16; this is the offer price, not a current market quote.
Base shares offered
216,034,482Base deal size at the final price; the over-allotment option is shown separately.
Gross base offering
$6.26BGross base offering value calculated from the disclosed base share count and IPO price; it is not net proceeds.
IpoHub score
How we score—Not rated
Balance sheet—
Growth—
Community—
Profitability—
Valuation—
Individual category scores are not available.
Where the money goes
$6.3BIPO raise
Use of proceeds—
Allocation percentages—
Net proceeds—
See the reported use of IPO proceeds below.
Reported use of proceeds
- use
- General corporate purposes, capital structure and transactions involving pre-IPO ownership interests.
- structure
- The upsized offering included new Class A shares and a full over-allotment option; the prospectus described sponsor ownership and structural transactions.
Key risks
Editorial analysisHospital budgets
Provider purchasing pressure can affect pricing and volumes.
Supply chain
Manufacturing, logistics and product availability are operationally critical.
Leverage and ownership
Debt and sponsor ownership shape capital allocation and public float.
Regulatory and quality
Medical products require quality systems, compliance and recalls management.
Final deal terms
- Ticker
- MDLN
- Exchange
- Nasdaq
- IPO valuation
- $37B
- IPO price
- $29.00
- Price range
- $26.00 – $29.00
- Pricing date
- Dec 16, 2025
- First trading day
- Dec 17, 2025
- Shares offered
- 216,034,482
- Deal size
- $6.3B
- Underwriters
- Not confirmed
- Greenshoe shares
- 32,405,172
- Lockup
- Not confirmed
- Quiet period expirations
- Not confirmed
Medline IPO: where and how to invest
Where can I invest in the Medline IPO?
Medline shares have a confirmed trading start on Nasdaq under the ticker MDLN. You can buy through a broker that supports that market and makes the shares available to your account. Check the venue, fees and current quote; the market price can differ from the original IPO offer price.
Can I buy Medline shares now?
Medline's public trading start is confirmed. Whether you can buy the stock in your account depends on your broker's market access and account rules. A stock-market order buys at available market prices; it is not an IPO allocation at the original offering price.
When is the Medline IPO?
Medline's confirmed first trading day was Dec 17, 2025. The offering was priced on Dec 16, 2025.
What is the Medline IPO share price?
Medline's confirmed IPO offer price is $29.00 per share. This is the offering price, not a live stock-market quote.
What is Medline's stock ticker and exchange?
The ticker recorded in this profile is MDLN. The exchange recorded here is Nasdaq.
Can I buy Medline shares before the IPO?
The Medline offering tracked here already has a confirmed trading start. Buying on the stock market now is therefore not a pre-IPO investment. Check the current quote and available share class with your broker.
Where can I find the Medline IPO prospectus?
Check Medline's official investor-relations announcements and publications from the relevant regulator and exchange. A confidential submission or an announcement about it is not a publicly available prospectus. Before subscribing, read the final prospectus for the risks, price, share class and offering terms.
More questions about the Medline IPO
What does Medline sell?
Medline manufactures and distributes medical supplies, procedure products and related services.
What was the IPO price?
The final IPO price was $29 per share.
Why was the deal large?
The offering involved more than 216 million base shares and a broad public-market capital structure.
What should investors watch?
Provider demand, pricing, supply-chain execution, quality, leverage and public float.
Similar IPOs
All IPOs →Not investment advice. Private market prices are dated model estimates. Community votes are not a recommendation.